151 related articles for article (PubMed ID: 34783361)
1. Enhanced clot lysis by a single point mutation in a reteplase variant.
Chen S; Chen D; Liu Y; Xu Y; Lin H; Cheng Y; Li J; Meng C; Liang M; Yuan C; Huang M
Br J Haematol; 2022 Feb; 196(4):1076-1085. PubMed ID: 34783361
[TBL] [Abstract][Full Text] [Related]
2. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
3. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M
Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502
[TBL] [Abstract][Full Text] [Related]
4. Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo.
Izadi S; Jalali Javaran M; Rashidi Monfared S; Castilho A
PLoS One; 2021; 16(11):e0260796. PubMed ID: 34847186
[TBL] [Abstract][Full Text] [Related]
5. Heterologous expression, purification and single step efficient refolding of recombinant tissue plasminogen activator (Reteplase) from E. coli.
Bhatt M; Masi HA; Patel A; Singh NK; Joshi C
Protein Expr Purif; 2024 Sep; 221():106504. PubMed ID: 38782082
[TBL] [Abstract][Full Text] [Related]
6. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
7. Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplase.
Härdig BM; Persson HW; Olsson SB
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):105-12. PubMed ID: 16479192
[TBL] [Abstract][Full Text] [Related]
8. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
9. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
10. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
12. Newer thrombolytic agents.
Verstraete M
Ann Acad Med Singap; 1999 May; 28(3):424-33. PubMed ID: 10575530
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
14. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
15. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
[TBL] [Abstract][Full Text] [Related]
16. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Grunwald MR; Hofmann LV
J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
[TBL] [Abstract][Full Text] [Related]
17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
19. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.
Jankun J; Keck R; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488
[TBL] [Abstract][Full Text] [Related]
20. Design and production of new chimeric reteplase with enhanced fibrin affinity: a theoretical and experimental study.
Mohammadi E; Mahnam K; Jahanian-Najafabadi A; Sadeghi HMM
J Biomol Struct Dyn; 2021 Mar; 39(4):1321-1333. PubMed ID: 32098615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
